Journal
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
Volume 13, Issue 6, Pages 283-293Publisher
SAGE PUBLICATIONS INC
DOI: 10.2310/7750.2009.08083
Keywords
-
Categories
Funding
- EMD Serono Canada
- Canadian Dermatology Association
- Amgen Wyeth
- Abbott Canada
- EMD Serono
- Ortho Biotech
- Shering Plough
- Bristol Myers Squibb
- Leo Pharma
- Steiffel Canada
- Galderma Canada
- Taro Pharma
Ask authors/readers for more resources
Background: The physical, mental, social, and financial burdens experienced by Canadians with psoriasis are relatively unexplored. Objective To gain an understanding of the impact of psoriasis on Canadians. Methods: An online survey, Stand Up and Speak Out, was provided to Psoriasis Education Program users who had given consent to be contacted. Results: Ninety-five percent of respondents had moderate to severe psoriasis, a high proportion relative to similar studies. Respondents reported medical and psychological comorbidities, with prevalence up to fourfold higher than Canadian background rates. Respondents also reported reduced income and increased unemployment, at levels that increased with psoriasis severity. Use of biologics was associated with high levels of satisfaction relative to other treatment options. However, biologic use was not uniform but was strongly correlated with insured status and annual income. Conclusion: In this severely affected population of Canadians with psoriasis, the physical, mental, social, and financial burden of disease was high.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available